Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 6, 2007
- BUSINESS NEWS IN BRIEF
August 6, 2007
- New Nycomed to Go Global through Partnering
August 6, 2007
- Makers' Accountability Essential to Implement JPMA's Proposal: FPMAJ President
August 6, 2007
- Exelon Skin Patch Recommended for European Approval: Novartis
August 6, 2007
- Metronidazole-Based 3-Drug Combination to Be Approved for Hp Eradication
August 6, 2007
- 10 New Drugs (6 APIs) Recommended for Approval
August 6, 2007
- REGULATORY NEWS IN BRIEF
August 6, 2007
- TOPICS／Asahi Kasei Publishes FY2007 IP Report
August 6, 2007
- NanoCarrier Obtains Patent on Macromolecular Micelles
July 30, 2007
- Adiponectin Stimulates Appetite in the Brain: Prof. Kadowaki
July 30, 2007
- R&D NEWS IN BRIEF(1)
July 30, 2007
- Schizophrenia Patients Must Be Treated with Fewer Drugs, at Lower Doses: Seminar
July 30, 2007
- R&D NEWS IN BRIEF(2)
July 30, 2007
- Revised Therapeutic GL on Breast Cancer Published
July 30, 2007
- NEW PRODUCTS
July 30, 2007
- Eisai to Launch 3 Major Drugs by FY2011: Mr Naito
July 30, 2007
- Prices Should Not Be Cut during Patent Life If Yakkasa Is Smaller than “Dispensing Margins”: EFPIA
July 30, 2007
- Long-Listed Drugs Should Be Priced Higher Than Generics: Mr Ohyagi
July 30, 2007
- REGULATORY NEWS IN BRIEF
July 30, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…